From: Camrelizumab for cancers in patients living with HIV: one-single center experience
Patient | Tumor type | PD-1 cycle | Response | Survival (yes/no) | TMB (mutes/Mb) | MSI | PD-L1 status (CPS) | Combined chemotherapy (yes/no) |
---|---|---|---|---|---|---|---|---|
#1 | Seminoma | 4 | Progression | Yes | N/A | N/A | N/A | No |
#2 | Gastric cardia cancer | 5 | Stable | Yes | N/A | N/A | N/A | No |
#3 | Renal carcinoma | 8 | Progression | Yes | 2.74 | MSS | < 1 | No |
#4 | Rectal carcinoma | 7 | Progression | No | N/A | N/A | N/A | No |
#5 | Non-Hodgkin lymphoma | 8 | PR | Yes | 8.21 | MSS | 20 | Yes |
#6 | Anal cancer | 6 | Progression | Yes | N/A | N/A | N/A | No |
#7 | Non-Hodgkin lymphoma | 7 | PR | Yes | N/A | N/A | N/A | Yes |
#8 | Cervical cancer | 6 | Stable | Yes | N/A | N/A | N/A | No |
#9 | Hepatocellular carcinoma | 7 | PR | Yes | N/A | N/A | N/A | No |
#10 | Renal carcinoma | 8 | Progression | No | N/A | N/A | N/A | No |
#11 | Renal pelvic cancer | 6 | Progression | No | 22.80 | MSS | < 1 | No |
#12 | Gastric cancer | 12 | Stable | Yes | N/A | N/A | N/A | Yes |
#13 | Renal carcinoma | 14 | Stable | Yes | N/A | N/A | N/A | No |
#14 | Penile carcinoma | 11 | Stable | Yes | N/A | N/A | N/A | No |
#15 | Bladder cancer | 12 | Stable | Yes | 7.30 | MSS | < 1 | No |
#16 | Bladder cancer | 26 | CR | Yes | 4.56 | MSS | 10 | Yes |
#17 | Bile duct cancer | 10 | PR | Yes | N/A | N/A | N/A | No |
#18 | Bladder cancer | 7 | Progression | Yes | N/A | N/A | N/A | No |
#19 | Bladder cancer | 5 | Progression | No | N/A | N/A | N/A | No |
#20 | Ureteral cancer | 8 | Progression | Yes | 20.98 | MSS | 2 | No |
#21 | Hepatocellular carcinoma | 7 | PR | Yes | 17.33 | MSS | 80 | No |
#22 | Bladder cancer | 6 | Stable | Yes | N/A | N/A | N/A | Yes |
#23 | Bladder cancer | 11 | CR | Yes | N/A | N/A | N/A | Yes |
#24 | Renal cancer | 6 | PR | Yes | N/A | N/A | N/A | No |